Intrahepatic Cholangiocarcinoma — Trials

Intrahepatic Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 86
Recruiting: 52
Ph III recruiting: 2
Growth YoY: +14.3%
Industry share: 9%
Top sponsor: Shanghai Zhongshan Hospital
Termination share: 47.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–44 of 44 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05712356	A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors(BOLSTER)	completed	Phase 2	66	Lisata Therapeutics, Inc.INDUSTRY	1	Sep 28, 2026	clinicaltrials
NCT01862315	Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)	completed	Phase 2	56	Memorial Sloan Kettering Cancer CenterOTHER